


RealRate

PHARMACEUTICAL 2019



Brooklyn ImmunoTherapeutics Inc. Rank 66 of 371





PHARMACEUTICAL 2019





Brooklyn ImmunoTherapeutics Inc. Rank 66 of 371

The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 751% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 191% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 386% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	6,785
Cost of Goods Sold	0
Intangible Assets	667
Liabilities, Current	4,024
Liabilities, Non-Current	0
Other Assets	2,745
Other Compr. Net Income	-145
Other Expenses	8,582
Other Liabilities	3,923
Other Net Income	-526
Property and Equipment	4,667
Research and Development	0
Revenues	23,335
Selling, General and Administrative Expense	14,486

Output Variable	Value in 1000 USD
Assets	14,864
Liabilities	7,947
Expenses	23,068
Stockholders Equity	6,917
Net Income	-259
Comprehensive Net Income	-332
Economic Capital Ratio	55%